What it's for (Indications)
- This pharmaceutical combination, comprising bufexamac, neomycin, and nystatin, is typically indicated for the topical treatment of various inflammatory dermatoses that are either complicated by or at high risk of secondary bacterial and/or candidal fungal infections.
- Such conditions may include eczematous dermatitis, intertrigo, or other superficial skin inflammations where an anti-inflammatory, antibacterial, and antifungal effect is desired concurrently.
- The bufexamac component addresses the inflammatory aspect, neomycin targets susceptible bacterial pathogens, and nystatin provides coverage against *Candida* species.
- Its use should be reserved for cases where the presence of all three components is clinically justified, considering the specific pathogens involved and the inflammatory state of the skin.
- Prescribers should always assess the risk-benefit profile, particularly given concerns regarding bufexamac’s safety profile.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The typical dosage involves applying a thin layer of the cream or ointment to the affected skin area(s) usually two to three times daily. The exact frequency and duration of treatment should be determined by a healthcare professional based on the severity and nature of the dermatosis, as well as the patient's response to therapy. Treatment duration is generally limited to avoid potential adverse effects, including the development of antibiotic resistance, sensitization, or skin changes from prolonged anti-inflammatory use. Patients should be instructed to gently massage the preparation into the skin until it is absorbed. Hands should be washed thoroughly before and after application to prevent spread of infection and cross-contamination. Avoid occlusive dressings unless specifically advised by a physician, as this can increase systemic absorption and the risk of adverse reactions, potentially leading to more pronounced side effects, particularly for neomycin. |
Safety & Warnings
Common Side Effects
- Adverse reactions associated with this combination primarily involve the skin at the application site.
- Common side effects may include local irritation, burning sensation, itching, redness, or stinging.
- A significant concern, particularly with the bufexamac component, is the potential for allergic contact dermatitis, which can manifest as worsening eczema, erythema, papules, vesicles, or even generalized skin reactions.
- Neomycin, an aminoglycoside, can cause hypersensitivity reactions and, with prolonged or extensive use on damaged skin, has a theoretical risk of systemic absorption leading to ototoxicity (hearing impairment) or nephrotoxicity (kidney damage), although this is rare with proper topical application.
- Nystatin is generally well-tolerated topically with minimal reported adverse effects.
- Other potential effects include skin atrophy, telangiectasia, striae (though bufexamac is not a steroid, altered skin integrity can occur), or secondary infections if the microbial balance is disturbed.
- Any signs of severe irritation or systemic effects warrant immediate medical consultation.
Serious Warnings
- Black Box Warning: ### SERIOUS SAFETY WARNING: RISK OF SEVERE ALLERGIC CONTACT DERMATITIS This combination product contains bufexamac, a non-steroidal anti-inflammatory drug, which has been associated with a high incidence of severe allergic contact dermatitis. This significant safety concern has led to the withdrawal of bufexamac-containing products from the market in several European countries due to the unacceptable risk-benefit profile. Patients using this medication are at substantial risk of developing severe hypersensitivity reactions, which may manifest as exacerbation of the underlying eczematous condition, development of new erythematous, pruritic, papular, or vesicular lesions, and in some cases, generalized eczema or systemic allergic reactions. The severity of these reactions can range from mild local irritation to widespread, debilitating skin conditions requiring intensive medical intervention. Healthcare providers must exercise extreme caution when prescribing this product and thoroughly assess the patient's history of allergic reactions, particularly to topical medications or NSAIDs. Patients should be explicitly warned about the potential for severe skin reactions and instructed to discontinue treatment immediately and seek medical attention if any signs of worsening skin condition or new allergic reactions occur. The risks associated with bufexamac must be carefully weighed against the potential benefits, especially when alternative treatments with more favorable safety profiles are available.
- This combination product requires careful consideration due to several important warnings.
- The most prominent concern is the significant risk of allergic contact dermatitis associated with bufexamac.
- This risk is so substantial that bufexamac-containing products have been withdrawn from the market in several European countries due to severe hypersensitivity reactions, including generalized eczema.
- Patients should be closely monitored for signs of worsening skin inflammation or new rashes.
- Prolonged or extensive use, especially on large surface areas or broken skin, increases the potential for systemic absorption of neomycin, raising a theoretical risk of ototoxicity and nephrotoxicity, particularly in patients with pre-existing renal impairment or those concurrently receiving other ototoxic/nephrotoxic drugs.
- The use of antibiotics can also lead to the overgrowth of non-susceptible organisms, including fungi (other than *Candida*) or resistant bacteria, necessitating discontinuation and alternative therapy.
- This preparation should not be used in or near the eyes, mucous membranes, or open wounds.
- Caution is advised in children and elderly patients due to potentially increased systemic absorption or altered metabolic function, respectively.
How it Works (Mechanism of Action)
This tripartite formulation exerts its therapeutic effects through the distinct mechanisms of its active components. **Bufexamac**, a non-steroidal anti-inflammatory drug (NSAID), functions by inhibiting the synthesis of prostaglandins, which are key mediators of inflammation. By reducing prostaglandin production, bufexamac helps to alleviate erythema, edema, and pruritus associated with inflammatory dermatoses. **Neomycin**, an aminoglycoside antibiotic, exerts its bactericidal action by irreversibly binding to the 30S ribosomal subunit of susceptible bacteria. This binding interferes with bacterial protein synthesis, leading to misreading of mRNA and the production of non-functional proteins, ultimately causing bacterial cell death. It is effective against a broad spectrum of Gram-negative bacteria and some Gram-positive bacteria. **Nystatin**, a polyene antifungal agent, acts by binding to ergosterol, a vital component of the fungal cell membrane. This binding leads to the formation of pores and disrupts the integrity of the cell membrane, resulting in the leakage of intracellular components and subsequent fungal cell death. Nystatin is particularly effective against *Candida* species.
Commercial Brands (Alternatives)
No other brands found for this formula.